Can ibuprofen and celecoxib help treat my depression?
Share
Depression was long explained mainly by low levels of brain chemicals such as serotonin and norepinephrine. Today we know it is more complex. Growing evidence shows that inflammation plays a role in some forms of depression, especially depression that does not improve with standard antidepressants and depression marked by a loss of pleasure and motivation (anhedonia). This has led researchers to test whether anti-inflammatory drugs, such as celecoxib, can help. This article explains what the research shows, how to use these medications safely and how your genes can help guide treatment.
How is inflammation linked to depression?
Inflammation is the body's natural way of fighting infection and healing injuries. Immune cells release chemical messengers called cytokines, which normally calm down once healing is done. When inflammation continues for a long time, these messengers can affect the brain, changing mood, energy, sleep and motivation. Many people notice low mood and tiredness after the flu, which is a short-term example of this effect.
C-reactive protein (CRP) is a common blood test for inflammation. Large studies have found that people with depression tend to have higher CRP levels. In a study of more than 73,000 people, higher CRP was linked to psychological distress and depression, and a US study of more than 14,000 people found that people with depression had about 31% higher CRP levels. Not everyone with depression has high inflammation: a 2019 analysis of 37 studies found that about 1 in 4 people with depression have low-grade inflammation (CRP above 3 mg/L).
Is depression with anhedonia linked to inflammation?
Anhedonia means losing interest or pleasure in activities you used to enjoy and having little motivation. It is common in depression and often responds poorly to standard antidepressants. Research shows that depression with anhedonia is associated with higher CRP levels. Inflammation appears to reduce the activity of dopamine-based reward circuits in the brain, which drive pleasure and motivation. In people with depression and high CRP, brain scans show weaker connections in these reward circuits.
This group may also respond better to adding anti-inflammatory treatment to antidepressants. In people with depression and CRP above 3 mg/L, an anti-inflammatory infusion (infliximab) reduced anhedonia compared with placebo, and increased motivation. Studies are now testing whether more accessible anti-inflammatory drugs, such as celecoxib, work best in people with anhedonia and high CRP.
Can anti-inflammatory drugs help depression?
Several clinical trials have tested adding an anti-inflammatory drug to an antidepressant:
- Celecoxib. A 2023 meta-analysis found that celecoxib 400 mg a day, added to an antidepressant for 6 weeks, improved depression symptoms more than the antidepressant alone, and appeared safe for up to 12 weeks.
- Anti-inflammatory drugs as a group. A 2019 meta-analysis of 36 trials found that anti-inflammatory add-ons improved response and remission rates, but all the studies had a high risk of bias, so the results need confirmation.
- Ibuprofen. There is little evidence that ibuprofen helps depression, and it has not been well studied as an add-on to antidepressants.
Anti-inflammatory drugs are not an approved treatment for depression, and the 2023 Canadian CANMAT depression guidelines do not recommend them for routine use. They should only be used under medical supervision.
Can a CRP blood test guide depression treatment?
CRP may help in some ways, but it is not yet standard practice. In one large study, people with higher CRP responded better to the antidepressant nortriptyline, while people with low CRP responded better to escitalopram. As noted above, people with high CRP and anhedonia may be more likely to benefit from anti-inflammatory treatment. If you have depression that has not improved with several antidepressants, ask your doctor whether a CRP test and other causes of inflammation should be checked.
Is it safe to take NSAIDs with antidepressants?
Anti-inflammatory painkillers (NSAIDs), such as ibuprofen, naproxen and celecoxib, can cause stomach ulcers and bleeding, raise blood pressure and affect the kidneys and heart, especially with long-term use. The CANMAT guidelines warn that combining SSRI or SNRI antidepressants with NSAIDs increases the risk of stomach bleeding. A stomach-protecting medication (a proton pump inhibitor) can lower this risk. Celecoxib is gentler on the stomach than older NSAIDs, but the bleeding risk still needs to be considered. Always check with your doctor or pharmacist before combining these medications.
How do genes affect NSAIDs and antidepressants?
- NSAIDs. Celecoxib, ibuprofen and meloxicam are broken down by the CYP2C9 enzyme. According to the CPIC guideline, CYP2C9 poor metabolizers clear these drugs much more slowly and should start celecoxib or ibuprofen at a lower dose (or choose another option), and avoid long-acting meloxicam, to lower the risk of bleeding and other side effects.
- Antidepressants. CYP2D6, CYP2C19 and CYP2B6 affect how you break down many antidepressants. The CPIC antidepressant guideline recommends dose changes or alternatives for poor and ultrarapid metabolizers. Read more in What are the best medications for anxiety?
How can a pharmacogenetic test help?
A Pillcheck test reports CYP2C9, CYP2D6, CYP2C19, CYP2B6 and other genes that affect anti-inflammatory painkillers, antidepressants and many other medications. Pillcheck reports on 24 genes, increasing coverage with new guidelines and drug labels (see the genes tab), and covers 355 medications, which account for over 70% of dispensed prescriptions. A Pillcheck pharmacist reviews your results together with all your medications, checks for interactions such as SSRIs with NSAIDs, and recommends safer options and doses to discuss with your prescriber.
Summary
- Inflammation is linked to some forms of depression, especially depression that does not respond to standard treatment.
- Depression with anhedonia is associated with higher CRP levels, and this group may respond better to adding anti-inflammatory treatment to antidepressants.
- Celecoxib added to an antidepressant improved depression in clinical trials; there is little evidence for ibuprofen.
- Anti-inflammatory drugs are not an approved depression treatment and should only be used under medical supervision.
- Combining SSRIs or SNRIs with NSAIDs increases the risk of stomach bleeding; a stomach-protecting medication can help.
- CYP2C9 affects NSAIDs, and CYP2D6, CYP2C19 and CYP2B6 affect many antidepressants.
Frequently asked questions
Can ibuprofen help with depression?
There is little evidence that ibuprofen helps depression. Most of the research on anti-inflammatory add-ons has studied celecoxib.
Does celecoxib work for depression?
Trials suggest that celecoxib added to an antidepressant can improve symptoms over 6 weeks, but it is not an approved depression treatment and should only be used under medical supervision.
What is anhedonia, and is it linked to inflammation?
Anhedonia is a loss of pleasure and motivation. Depression with anhedonia is associated with higher CRP levels, and people with high CRP may benefit more from anti-inflammatory treatment.
Is it safe to take Advil with my antidepressant?
Occasional use is usually fine, but regular use of NSAIDs with SSRIs or SNRIs increases the risk of stomach bleeding. Ask your pharmacist, especially if you take them often or are older.
Should I ask for a CRP test?
If your depression has not improved with several treatments, ask your doctor whether checking CRP and other signs of inflammation makes sense for you.
References
Wium-Andersen MK, Ørsted DD, Nielsen SF, Nordestgaard BG. Elevated C-reactive protein levels, psychological distress, and depression in 73,131 individuals. JAMA Psychiatry. 2013;70(2):176-184.
Cepeda MS, Stang P, Makadia R. Depression Is Associated With High Levels of C-Reactive Protein and Low Levels of Fractional Exhaled Nitric Oxide: Results From the 2007-2012 National Health and Nutrition Examination Surveys. J Clin Psychiatry. 2016;77(12):1666-1671.
Osimo EF, Baxter LJ, Lewis G, Jones PB, Khandaker GM. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. Psychol Med. 2019;49(12):1958-1970.
Bekhbat M, Li Z, Mehta ND, et al. Functional connectivity in reward circuitry and symptoms of anhedonia as therapeutic targets in depression with high inflammation: evidence from a dopamine challenge study. Mol Psychiatry. 2022;27(10):4113-4121.
Singh A, Bekhbat M, Goldsmith DR, et al. Lipids and C-reactive protein predict anhedonia and reward circuit functional connectivity responses to anti-cytokine and dopaminergic therapies in patients with depression. Compr Psychoneuroendocrinol. 2025;21:100284.
Treadway MT, Etuk SM, Cooper JA, et al. A randomized proof-of-mechanism trial of TNF antagonism for motivational deficits and related corticostriatal circuitry in depressed patients with high inflammation. Mol Psychiatry. 2025;30(4):1407-1417.
Gędek A, Szular Z, Antosik AZ, et al. Celecoxib for Mood Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2023;12(10):3497.
Köhler-Forsberg O, N Lydholm C, Hjorthøj C, et al. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatr Scand. 2019;139(5):404-419.
Uher R, Tansey KE, Dew T, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry. 2014;171(12):1278-1286.
Lam RW, Kennedy SH, Adams C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults. Can J Psychiatry. 2024;69(9):641-687.
Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200.
Bousman CA, Stevenson JM, Ramsey LB, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68.